Shyra Gardai, chief scientific officer at the molecular glue start-up EpiBiologics, says Big Pharma’s recent interest in glue ...

GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...